Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$21.07 USD

21.07
3,805,995

+0.57 (2.78%)

Updated Oct 15, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.

How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Here's How STERIS (STE) is Placed Ahead of Q1 Earnings

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.

Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.

Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings

by Zacks Equity Research

Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.

Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Comcast (CMCSA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Comcast's (CMCSA) second-quarter 2024 results are expected to reflect a slowing broadband subscriber base, offset by the steady performance of theme parks and the Peacock streaming service.

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

by Zacks Equity Research

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense

by Zacks Equity Research

Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.

Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.

Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why

by Zacks Equity Research

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.11, indicating a +1.18% shift from the previous trading day.

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop

by Zacks Equity Research

Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.

Integra's (IART) New Site to Produce Recalled Tissue Products

by Zacks Equity Research

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

by Zacks Equity Research

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

by Zacks Equity Research

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.

Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

by Zacks Equity Research

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.

Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services

by Zacks Equity Research

Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.